Novartis Touts Ligelizumab As Xolair Successor In CSU
Filing Planned For 2021
Novartis and Roche's Xolair was approved as a treatment for hives in 2014 and has transformed treatment for patients with severe symptoms. New data on the former's new IgE inhibitor suggest that a more effective drug could be on the way.
You may also be interested in...
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.
Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.
The Swiss major's old guard of oncology products continue to falter but Roche's new wave of treatments is helping to keep the financials fairly healthy.